METHADOSE

Post-LOE

methadone hydrochloride

Hikma

ANDAORALTABLET, FOR SUSPENSION

Approved

Apr 1993

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

METHADOSE (methadone hydrochloride) by Hikma is mu-agonist; a synthetic opioid with multiple actions qualitatively similar to those of morphine, the most prominent of which involves the central nervous system and organs composed of smooth muscle. Approved for severe, persistent pain, including immediate-release opioids. First approved in 1993.

Drug data last refreshed 20h ago

Mechanism of Action

mu-agonist; a synthetic opioid with multiple actions qualitatively similar to those of morphine, the most prominent of which involves the central nervous system and organs composed of smooth muscle. The methadone withdrawal syndrome, although qualitatively similar to that of morphine, differs in…

Indications (3)

severe persistent pain

Worked on METHADOSE at Hikma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.